Identifying markers for cardiovascular outcomes in stroke patients
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke
This study is trying to find new blood and imaging markers that can help predict how well stroke patients will respond to treatment and what their future health might look like.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Bron) |
| Trial ID | NCT05263804 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients who have experienced ischemic stroke, aiming to identify new biological and imaging markers that can predict treatment response and prognosis. By collecting blood samples and conducting MRI imaging, researchers will create a comprehensive bio- and imaging-collection that can enhance understanding of stroke outcomes. The study also seeks to establish a clinical database that can serve as a valuable resource for future research and quality of care assessments.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have experienced a confirmed ischemic stroke and are eligible for thrombolysis or thrombectomy.
Not a fit: Patients with progressive or uncontrolled cancer, or those who cannot be followed up at the study site, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better prognostic tools for patients who have suffered an ischemic stroke.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for stroke outcomes, but this specific approach of combining biological and imaging markers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Ischemic Stroke confirmed by MRI * Proximal arterial occlusion (M1 and/or M2) * Eligible for thrombolysis and/or thrombectomy * Informed consent signed by the patient or the next of kin * Patient with a social security number Ancillary Study Inclusion Criteria: * Eligible for the Hibiscus stroke II cohort * Ancillary study informed consent signed by the patient or the next of kin Exclusion Criteria: * Patients for whom it is known at the inclusion that follow-up at 3 months will not be possible at Pierre Wertheimer Hospital (Lyon, France) * Patient with progressive or uncontrolled cancer. * Deprivation of civil rights * Pregnant woman or woman of childbearing age without proof of the absence of a current pregnancy * For patients participating in the optional fecal library: factors leading to a potential change in microbiota (antibiotic therapy within 3 months, probiotic or rebiotic use within 3 months, ileo or gastrostomy, gastrointestinal resection surgery, bariatric or peptic ulcer surgery, Crohn's disease or chronic inflammatory bowel disease, helicobacter pylori gastric ulcer less than 1 year old, participation in a study that aims to modify the microbiota) Ancillary Study Exclusion Criteria: * Contraindication to MRI with gadolinium injection * Contraindication to cardiac MRI (including inability to perform cardiac MRI) * Patients with a glomerular filtration rate \<30ml/min * History of coronary artery disease
Where this trial is running
Bron
- Hôpital Pierre Wertheimer, GHE — Bron, France (Recruiting)
Study contacts
- Study coordinator: Tae-Hee CHO, MD, PhD
- Email: tae-hee.cho@chu-lyon.fr
- Phone: +33 4 72 35 71 70
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.